LQDA Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Liquidia (NASDAQ: LQDA)
›
Liquidia (NASDAQ: LQDA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 216 employees.
The shares were at 56.63 USD on 19 November 2026, up 121.2% over 52 weeks. Its 52-week range is 22.31 USD to 93.61 USD: the price is 39.5% below the high and 153.8% above the low.
Its market capitalisation is 5.10B USD.
Liquidia reports return on equity of -154.0%, an operating margin of 47.1% and revenue up 314.6% year over year.
It holds more cash than debt, a net cash position of 227.33M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 66.13 USD is 16.8% above the current price. The next earnings report is expected on 11 March 2027.